1201935-98-9Relevant academic research and scientific papers
Focal adhesion kinase inhibitor and use
-
Paragraph 0583; 0585; 0586, (2019/01/08)
The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.
Two-directional approach for the rapid synthesis of 2,4-bis-aminoaryl pyridine derivatives
Morgentin, Remy,Barlaam, Bernard,Foote, Kevin,Hassall, Lorraine,Hawkins, Janet,Jones, Clifford D.,Le Griffon, Antoine,Peru, Aurelien,Ple, Patrick
experimental part, p. 8 - 24 (2011/10/18)
We have developed two different approaches in parallel to rapidly access 2,4-bis aminoaryl pyridine compounds from a common starting material. The C-4/C-2 approach uses palladium-mediated coupling reactions to sequentially functionalize C-4 and then C-2. An alternative C-2/C-4 route uses a regioselective SNAr reaction to first substitute at C-2 then subsequently at C-4 by a palladium-mediated reaction. Both approaches have been used successfully to provide a range of 2,4-bis-aminoaryl pyridine compounds.
PYRIDINE COMPOUNDS
-
Page/Page column 231, (2010/01/12)
The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.
